• Nasdaq grants Jaguar Health extension until May 15, 2026, to meet $1.00 bid price requirement
• Company to implement 1-for-35 reverse stock split effective April 30, 2026
• Shares will trade on a split-adjusted basis under ticker JAGX
• Move follows shareholder approval at April 2026 special meeting
• Compliance requires minimum $1.00 closing bid for 10 consecutive business days
Jaguar Health has received an extension from the Nasdaq Hearings Panel to regain compliance with the exchange’s minimum bid price requirement, providing the company until May 15, 2026, to meet the $1.00 per share threshold for continued listing on the Nasdaq Capital Market.
To support compliance, the company announced it will implement a 1-for-35 reverse stock split of its common stock, effective April 30, 2026. Following the split, shares will begin trading on an adjusted basis under the existing ticker symbol, JAGX.
Reverse split mechanics and compliance timeline
Under the reverse stock split, every 35 shares of issued and outstanding common stock will be consolidated into one share, with no change to par value. Fractional shares will not be issued; instead, stockholders will receive cash in lieu of fractional holdings.
To regain compliance, Jaguar must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the May 15 deadline. Nasdaq may allow an additional review period of up to 20 business days following this requirement.
Shareholder approval and administrative process
The reverse stock split was approved by shareholders during a special meeting held in April 2026. The company has appointed Equiniti Trust Company, LLC as the exchange agent to manage the transition for registered shareholders, while those holding shares through brokerage accounts will not need to take action.
Broader company focus
Jaguar Health develops plant-based prescription therapies targeting gastrointestinal diseases, with subsidiaries focused on rare and orphan conditions such as microvillus inclusion disease and short bowel syndrome. The company also has initiatives exploring plant-derived therapeutics for mental health indications.
The compliance effort reflects ongoing financial and operational steps aimed at maintaining Nasdaq listing status while advancing its therapeutic development programs.
Information sourced from the company’s press release.
